Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease
- PMID: 22093501
- DOI: 10.1016/j.jacc.2011.08.051
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease
Erratum in
- J Am Coll Cardiol. 2012 Apr 17;59(16):1491
Abstract
Chronic kidney disease (CKD) is prevalent and affects an ever-increasing proportion of patients presenting with acute coronary syndrome (ACS). Patients with CKD have a higher risk of ACS and significantly higher mortality, and are also predisposed to increased bleeding complications. Antiplatelet and antithrombotic drugs form the bedrock of management of patients with ACS. Most randomized trials of these drugs exclude patients with CKD, and current guidelines for management of these patients are largely based on these trials. We aim to review the safety and efficacy of these drugs in patients with CKD presenting with ACS.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Dabigatran is not a direct Xa inhibitor.J Am Coll Cardiol. 2012 Apr 17;59(16):1490; author reply 1490. doi: 10.1016/j.jacc.2012.02.006. J Am Coll Cardiol. 2012. PMID: 22497832 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
